Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Bullboard Posts
Post by hydrabioon Jul 24, 2017 8:31am
117 Views
Post# 26500445

Reality

Reality
I don't understand why all the discussions about if Aziz is the right guy or Bob is the right guy. Honestly, neither are sales people, neither have a proven track record, neither have had any success with Vanc. Many small generic companies have come into Canada, launched a few products and got heir fair share of sales. Vanc has not. Vanc is simply a sales office as they only have contracts for in-licensing. Please look into Bill 81 in Quebec. Some generics products will drop to 10% of brand and all Pan-Canadian products will also decrease. A lot of provinces are keeping a close eye on the savings Quebec will realize and it will not be long before other provinces drop as well. So now do the math: Vanc's acquisition price has to be higher then the current generic manufacturers COGS (the manufacture needs to make $) take the math ive done on here brfore (2% prompt pay, 5%-8% fee for distribution, and customers still demanding 65%-80% in allowances) now also add 2%-3% of what will come back in way of returns. Some manufacturers that are vertically integrated are having problems with making profit but we are led to believe that, with a declining generic price, minimal cap on pharmacy allowances and Vanc having contract manufacturing, they will be successful? Please take a look at Bill 81 in Quebec and do your own DD and asses the impact that will come in the future.
Bullboard Posts